Chapter 27 Solvents Blocked: Notification 09/2022 for Pharma Refund Teams

An API-centric Tier-2 integrated pharma manufacturer running its principal Chapter 29 active pharmaceutical ingredient unit at Vishakhapatnam in Andhra Pradesh reconciles its solvent purchase register for October 2025. Hexane consumed in extraction, isopropyl alcohol in crystallisation wash, methanol in reactor flushes, toluene in azeotropic distillation, and methyl ethyl ketone in the final purification step together aggregate to a monthly solvent purchase of the order of Rs 24 crore — 15 to 25 percent of the unit’s total raw-material cost depending on the therapy mix in production for that period. At 18 percent GST, the solvent purchase generates Rs 4.32 crore of input tax credit for the tax period. The unit’s Chapter 29 API output sits at 5 percent GST under HSN heading 2941 for antibiotic APIs and the Chapter 29 residuum for other organic-chemical APIs. The inverted-rate arithmetic is worse for the API unit than for a downstream Chapter 30 formulator — solvents are a larger proportion of the input base, and CBIC Notification 09/2022-Central Tax (Rate) dated 13 July 2022 sits on the Chapter 27 solvent leg with a legal footprint that field-level scrutiny has broadened well beyond the direct output-side wording of the notification. The refund-team question is direct: does the Rs 4.32 crore of Chapter 27-adjacent solvent ITC feed the monthly Rule 89(5) refund claim under Form GST RFD-01, or is it a permanent cost that must be projected into a Rs 40 to 55 crore annual working-capital lock-up? This article is the segregation discipline that Indian pharma indirect-tax leads apply to answer that question defensibly.

Quick reference

The reconciliation in one paragraph

A Chapter 29 API manufacturer sells its output at 5 percent GST under HSN heading 2941 for antibiotics or the Chapter 29 residuum for other organic-chemical APIs. Its solvent input base — hexane at HSN 2710, isopropyl alcohol at HSN 2905.12, methanol at HSN 2905.11, toluene at HSN 2902.30 and methyl ethyl ketone at HSN 2914.12 — sits at 18 percent GST and contributes 15 to 25 percent of total raw-material cost. Every tax period locks structural unutilised inverted-duty credit into the electronic credit ledger. Section 54(3) of the CGST Act 2017 permits refund; Rule 89(5) of the CGST Rules 2017, as amended prospectively by Notification 14/2022-Central Tax dated 5 July 2022, gives the formula. Notification 09/2022-Central Tax (Rate) dated 13 July 2022, effective 18 July 2022, invokes clause (ii) of the first proviso to Section 54(3) and bars refund of unutilised ITC on output supplies falling under Chapter 15 (edible oils) or Chapter 27 (mineral fuels, mineral oils, distillation products). The direct statutory footprint is output-side — a Chapter 29 API output is not itself barred. The reconciliation surface is input-side, where field-level scrutiny by proper officers has adopted the position that the notification’s spirit of denying refund to the petroleum-derived-input value chain flows through to the downstream buyer’s Net ITC composition. The refund team’s monthly workbook holds a base-case computation (Chapter 27 solvent included in Net ITC, defensible legal position per Union of India v. VKC Footsteps) and a carved-out computation (Chapter 27 solvent segregated into a blocked-refund bucket, conservative field-level position), with the Statement 1A invoice-level annexure disclosing the solvent leg transparently and the working-capital plan projecting the segregated bucket into an annualised lock-up.

What the scenario looks like in India

Indian API manufacturing is geographically concentrated in Andhra Pradesh and Telangana. Vishakhapatnam anchors a large slice of national bulk-drug capacity because of port access for imported starting materials (a material share of Chinese-origin key starting materials from Zhejiang, Jiangsu and Shandong provinces enters through Visakhapatnam and Chennai), proximity to the Hyderabad formulation cluster for downstream forward integration, and the state’s historical incentive framework for pharma investment. Bachupally and Bollaram in Telangana form the second concentration — Dr Reddy’s Bollaram integrated bulk-drug complex is the reference footprint, with Aurobindo Pharma and Divi’s Laboratories’s Hyderabad operations rounding out the belt. Kakinada in Andhra Pradesh anchors a smaller specialty-molecule and antibiotic-API cluster. Ankleshwar in Gujarat, Kurkumbh in Maharashtra and Ahmednagar in Maharashtra complete the geographic spread; each site sits under a separate state GSTIN and files its own monthly Form GST RFD-01 refund claim against the accumulated inverted-duty ITC.

Illustrative Tier-2 API-centric listed manufacturers running Chapter 29 output at the scale relevant to this reconciliation include Divi’s Laboratories, Laurus Labs, Neuland Laboratories, Granules India, Suven Pharma, and the API businesses within Aurobindo Pharma and Piramal Pharma. CDMO and CRAMS players — Syngene International (the Biocon subsidiary), Aragen Life Sciences (formerly GVK Bio) and the contract-manufacturing units within Piramal Pharma — carry a similar solvent-input profile although the refund workbook layers additional complexity from the CDMO customer’s principal-side ownership of the API. Tier-1 integrated formulators with backward-integrated API capacity — Sun Pharmaceutical Industries at select bulk-drug plants, Dr Reddy’s Laboratories at Bollaram, Cipla at select API sites — run a hybrid inversion where the API unit’s solvent segregation feeds up through an internal transfer-pricing register into the formulation plant’s Rule 89(5) workbook. For the reconciliation this article walks through, the reference persona is a Tier-2 API-centric manufacturer with a principal Chapter 29 output unit at Vishakhapatnam sized at monthly solvent purchase of the order of Rs 24 crore and annual API-unit turnover in the Rs 1,800 to 2,500 crore band. The plant’s monthly Chapter 27-adjacent solvent ITC of Rs 4.32 crore is the segregation surface the article walks in worked-example detail.

The regulatory overlay — Section 54(3), Rule 89(5), and the input-side footprint of Notification 09/2022

Notification 09/2022-Central Tax (Rate) dated 13 July 2022, effective 18 July 2022, is issued under clause (ii) of the first proviso to sub-section (3) of Section 54 of the Central Goods and Services Tax Act 2017 on the recommendations of the GST Council. It notifies the goods in respect of which no refund of unutilised input tax credit shall be allowed under the inverted-duty structure limb of Section 54(3). Two categories are notified — HSN Chapter 15 (animal or vegetable fats and oils; prepared edible fats; waxes) and HSN Chapter 27 (mineral fuels, mineral oils and products of their distillation; bituminous substances; mineral waxes). The notification is prospective — the bar applies to refund claims on unutilised ITC accumulated on or after 18 July 2022. The direct statutory footprint sits on the output side. A manufacturer whose finished goods fall under Chapter 15 or Chapter 27 cannot claim inverted-duty refund on its own inversion cycle regardless of its input rates — the Agro cluster’s edible oil Chapter 15 IDS refund blocked walkthrough covers the same statutory mechanic on the edible-oil side and is the reference cross-cluster anchor for pharma refund teams reading Notification 09/2022 for the first time.

The Supreme Court in Union of India v. VKC Footsteps India Pvt Ltd (2021) 10 SCC 674 upheld the constitutional validity of clause (ii) of the first proviso to Section 54(3) and Rule 89(5). The Constitution Bench held that refund of unutilised ITC on the inverted-duty structure limb is a statutory concession rather than a constitutional right — the legislature and the Council are entitled to notify categories of supplies in respect of which the refund is disallowed. The judgment underpins the enforceability of Notification 09/2022 and is the reference anchor cited in every refund claim scrutiny where the Chapter 27 solvent segregation is questioned.

Rule 89(5) of the CGST Rules 2017, as amended by Notification 14/2022-Central Tax dated 5 July 2022, gives the refund formula. Maximum Refund Amount = (Turnover of inverted-rated supply of goods and services x Net ITC / Adjusted Total Turnover) minus (Tax payable on such inverted-rated supply x Net ITC / ITC availed on inputs and input services). Net ITC in the numerator excludes input services and capital goods. For a Chapter 29 API manufacturer running the conservative segregation discipline against Notification 09/2022 field-level scrutiny, Net ITC also carves out the Chapter 27 solvent leg. The Rule 89(5) inverted duty refund pharma formulations complete guide is the Wave A cornerstone that walks the formula in end-to-end detail and is the reference for the full refund workbook that this article’s segregation discipline feeds into.

The reconciliation surface where the notification’s practical footprint concentrates for a Chapter 29 API manufacturer is input-side. Field-level scrutiny by proper officers has adopted the position that the notification’s spirit of denying refund to the petroleum-derived-input value chain flows through the buyer’s Net ITC composition — some officers apply a proportional carve-out on the Chapter 27 solvent leg on the interpretation that the notification treats the entire Chapter 27 value chain (including downstream buyers) as outside the refund perimeter. The defensible legal position, supported by the Wave A cornerstone and the API vs formulation HSN 2941/3003/3004 reconciliation guide, is that Chapter 27 solvent inputs consumed in a Chapter 29 output remain eligible ITC and eligible Net ITC. Whether the API manufacturer adopts the defensible legal position or the conservative segregation position is a management judgement that turns on the manufacturer’s historical scrutiny experience at the jurisdictional office, the appetite for the deficiency-memo response cycle, and the working-capital cost of holding the segregated bucket versus the litigation cost of defending the base-case claim.

A worked example — an illustrative Vishakhapatnam Chapter 29 API unit at monthly close

Illustrative — the following figures represent the operating pattern of a Tier-2 API-centric pharma manufacturer running a principal Chapter 29 output unit at the scale that Indian listed API refiners operate. Public disclosures do not reveal per-plant per-month solvent segregation quantum at the granularity below; cross-verify against your own plant’s GSTR-1 and GSTR-2B extracts before action.

The API unit closes October 2025 with the following inward supply position on the solvent leg, converted to Rs crore for the tax period:

The unit’s aggregate outward supply for the tax period is Rs 190 crore of Chapter 29 API at 5 percent GST — output tax payable of Rs 9.50 crore. Non-solvent inputs — key starting materials (imported and domestic), reagents, catalysts, excipients and packaging — total Rs 132 crore across a mix of 5 percent, 12 percent and 18 percent GST-rated inputs, generating Rs 15.84 crore of ITC. Input services (freight, external analytical laboratory, engineering consulting, plant maintenance) contribute Rs 2.16 crore of ITC that is excluded from Net ITC per Rule 89(5). Capital goods (reactor and column additions) contribute Rs 0.81 crore of ITC that is also excluded from Net ITC.

Two parallel Rule 89(5) computations run in the workbook. The base-case (defensible legal position, Chapter 27 solvent included) puts Net ITC at Rs 15.84 + 4.32 = Rs 20.16 crore. Turnover of inverted-rated supply is Rs 190 crore. Adjusted Total Turnover is Rs 190 crore. ITC availed on inputs and input services (the denominator of the second-limb ratio) is Rs 20.16 + Rs 2.16 = Rs 22.32 crore. First limb = (190 x 20.16 / 190) = Rs 20.16 crore; second limb = (9.50 x 20.16 / 22.32) = Rs 8.58 crore; maximum refund = 20.16 - 8.58 = Rs 11.58 crore for the tax period.

The carved-out case (conservative field-level position, Chapter 27 solvent segregated) puts Net ITC at Rs 15.84 crore. First limb = (190 x 15.84 / 190) = Rs 15.84 crore; second limb = (9.50 x 15.84 / 22.32) = Rs 6.74 crore; maximum refund = 15.84 - 6.74 = Rs 9.10 crore. The difference of Rs 2.48 crore is the tax-period refund at risk on the Chapter 27 solvent leg alone. Annualised, the segregated bucket sits at Rs 4.32 crore x 12 = Rs 51.84 crore of Chapter 27-adjacent ITC that either feeds the base-case refund claim (and defends at scrutiny) or drops into a permanent working-capital lock-up in the Rs 40 to 55 crore per major refiner range.

The Statement 1A invoice-level annexure discloses the Chapter 27 solvent leg on a distinct line, with the invoice-level solvent register attached as supporting documentation. Whichever position the finance team adopts, the transparent disclosure is what defends the claim at scrutiny — an aggregate ITC pool without the solvent leg broken out invites a deficiency-memo cycle regardless of the underlying legal reading.

The solvent recovery cycle and its ITC treatment

Modern Chapter 29 API units run a solvent-recovery cycle where used solvent from process reactors is distilled and returned to inventory for a second-cycle or third-cycle process use. Recovery efficiency runs 60 to 80 percent for hexane, 50 to 70 percent for isopropyl alcohol and methanol, and 40 to 60 percent for toluene and methyl ethyl ketone, depending on the impurity load and the distillation column design. Recovery reduces net solvent consumption materially — for the reference persona, primary solvent purchase of Rs 24 crore per month combined with a solvent-recovery cycle that returns approximately 45 percent of used solvent to inventory reduces the effective solvent-cost intensity of the API unit by approximately Rs 10.8 crore per month against a hypothetical zero-recovery baseline.

The GST-and-refund treatment of the recovery cycle is straightforward. Solvent recovery within the same GSTIN is not a supply under Schedule I of the CGST Act — captive-use inventory transfer within a single registration does not attract output GST and does not generate incremental ITC. The recovery cycle does not itself add to the Chapter 27-adjacent solvent ITC bucket. The utilities consumed in the recovery cycle — the steam or thermic-fluid heating for the distillation column, the cooling water, the electricity — carry their own input tax credit that sits in the general utilities bucket and is a regular Net ITC input, not part of the segregated Chapter 27 bucket. The reconciliation discipline is to hold the utilities ITC separate from the solvent ITC in the workbook — folding recovery-cycle utilities into the segregated Chapter 27 bucket over-states the segregation exposure and under-states the Rule 89(5) refund.

Environmental compliance for spent solvent — the residuum that cannot be recovered and must be disposed as hazardous waste — is tracked under the state pollution control board regime (Maharashtra Pollution Control Board for the Kurkumbh belt, Gujarat Pollution Control Board for the Ankleshwar belt, and the Andhra Pradesh Pollution Control Board and Central Pollution Control Board framework for the Vishakhapatnam and Kakinada belts). The environmental register is separate from the refund workbook and does not itself interact with the Chapter 27 solvent segregation, but a spent-solvent disposal contract with a hazardous-waste handler generates its own input service ITC that follows the standard exclusion from Net ITC under Rule 89(5) — the input service ITC is availed as ordinary ITC in the electronic credit ledger but does not feed the Rule 89(5) numerator.

Common reconciliation breakages

Five breakages recur across Indian Chapter 29 API manufacturers running the monthly refund cycle post-Notification 09/2022, and each maps to a specific control failure that either invites a deficiency memo in Form GST RFD-03 or under-states the working-capital lock-up projection.

• Solvent invoice not tagged to the segregation bucket at capture. The most common failure is a solvent invoice booked into the general raw-material ITC pool at the accounting-system capture step without an HSN chapter tag. When the month-end refund workbook is built, the finance team cannot mechanically segregate the Chapter 27 solvent leg without a manual re-classification pass against the master solvent-supplier list — an error-prone exercise that either misses invoices (under-segregating and over-claiming refund) or over-includes non-solvent Chapter 29 organic chemicals (over-segregating and under-claiming refund). The fix is to tag the HSN chapter at the purchase-order stage and inherit the tag through the goods-receipt-note and invoice-booking cycle.

• Confusion between Chapter 27 and Chapter 29 boundary. Hexane at HSN 2710 sits in Chapter 27; isopropyl alcohol at 2905.12, methanol at 2905.11, toluene at 2902.30 and methyl ethyl ketone at 2914.12 sit in Chapter 29. The Notification 09/2022 statutory language covers Chapter 27 goods; the field-level segregation position treats the wider Chapter 27-adjacent solvent value chain as one bucket. Finance teams that segregate only the Chapter 27 (hexane) leg under-state the segregation exposure by 60 to 70 percent depending on the solvent mix — the field-level position expects the full solvent bucket. The fix is to run the segregation on the process-use bucket (all five workhorse solvents) and disclose the technical HSN mapping in a footnote on the Statement 1A annexure.

• Solvent recovery cycle mis-attribution. The recovery cycle is internal captive use with no supply and no incremental ITC. Finance teams that erroneously accrue a notional “recovered solvent ITC” against the base-case refund claim create a spurious ITC entry that fails at scrutiny. Conversely, folding the recovery-cycle utilities (steam, cooling water, electricity) into the segregated Chapter 27 bucket over-states the segregation exposure. The fix is a clear reconciliation rule — recovery cycle generates no incremental ITC; utilities ITC stays in the general Net ITC pool.

• Working-capital lock-up projection missing the electronic credit ledger utilisation prospect. The segregated Chapter 27 solvent ITC does not disappear from the electronic credit ledger — it sits there and can be utilised against future output tax on any non-inverted-rated supply the manufacturer has (a rare occurrence for a pure API manufacturer but a real utilisation prospect for a hybrid API-plus-formulation manufacturer). Finance teams that project the entire segregated bucket as a permanent working-capital lock-up over-state the lock-up if the manufacturer has any non-inverted output. The projection should test the electronic credit ledger’s forward utilisation trajectory against the segregated bucket’s accumulation and only treat the residual as a permanent lock-up.

• Management-judgement write-off timing mis-applied. The segregated bucket is a management-judgement write-off candidate at the 12 to 18 month mark if the electronic credit ledger utilisation prospect is negative. Writing off too early (before 12 months) violates the prudence principle of Ind AS 8 and Ind AS 37 — the ITC balance is technically available for utilisation and cannot be treated as permanently lost. Writing off too late (beyond 24 months) creates a misleading balance sheet — a static ITC balance that has no realistic utilisation prospect distorts the working-capital position. The fix is a defined 15-month test with a documented management-judgement note explaining the utilisation projection at each reporting date.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the plant-level GSTR-2B auto-populated ITC statement, the accounting-system solvent purchase register with HSN chapter tagging at the purchase-order stage, and the plant’s process-use master, and produces a monthly Rule 89(5) refund workbook that holds both the base-case (Chapter 27 solvent included in Net ITC, defensible legal position) and the carved-out case (Chapter 27 solvent segregated per Notification 09/2022 field-level position) in parallel. The Statement 1A invoice-level annexure discloses the solvent leg on a distinct line. The working-capital lock-up projection register aggregates the segregated bucket by tax period and by financial year and holds the 15-month management-judgement write-off decision framework against the electronic credit ledger utilisation trajectory. Match rate improvement of 51 to 88 percent on the plant-level GSTR-2B to accounting ITC reconciliation, combined with an ISO 27001:2022 posture, AWS Mumbai hosting and DPDP Act 2023 aligned data handling, is what makes the platform an infrastructure investment for a Tier-2 API-centric pharma manufacturer running a multi-crore monthly solvent segregation exposure rather than a spreadsheet substitute.

Cross-cluster bridges and where to read next

The Chapter 27 solvent segregation walked in this article is the input-side reading of Notification 09/2022. For the direct output-side reading of the same notification, the Agro cluster’s edible oil Chapter 15 IDS refund blocked walkthrough covers the parallel mechanic on the Chapter 15 edible-oil refiner side where the refund bar sits on the output goods themselves and the working-capital lock-up runs at Rs 75 to 100 crore per year per major refiner. The dairy inverted-duty refund under Rule 89(5) post GST 2.0 walkthrough covers a Chapter 4 output where the refund is admissible — the counterfactual reference for pharma refund teams to appreciate how much the Notification 09/2022 field-level position costs a Chapter 29 API manufacturer that runs a heavy solvent input base.

Within the pharma cluster, the Rule 89(5) inverted duty refund pharma formulations complete guide is the Wave A cornerstone that walks the full refund workbook for a Chapter 30 formulator; the segregation discipline this article establishes is the input-side complement to that workbook. The API vs formulation HSN 2941/3003/3004 reconciliation guide is the Theme 3 cornerstone that unpacks the Chapter 29 versus Chapter 30 boundary in end-to-end detail. The methodology framework for building the per-plant per-tax-period reconciliation workbook — mapping every input HSN chapter to a distinct reconciliation surface, holding both base-case and defence-case computations, and building the deficiency-memo response cycle into the standing close process — sits in Terra Insight’s own reconciliation failure mode analysis pillar and the reconciliation playbook for monthly close operations pillar.

The commercial pillar for the pharma sub-cluster is Pharma reconciliation software India; the broader authority for the platform is reconciliation software India with the specialised GST reconciliation software surface for the Section 54(3) refund workflow. Finance teams evaluating the segregation discipline against their own current-state workbook should read the pharma-cluster hub at /insights/pharma/ to place the Notification 09/2022 walkthrough in the wider set of Wave A and Wave B pharma refund and reconciliation surfaces.

The five FAQs below address the operational questions Indian pharma indirect-tax leads and API-unit controllers ask most often when building a standing monthly Chapter 27 solvent segregation discipline against Notification 09/2022.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 15 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024